Random-effects regression models were
used to compare randomization groups
over time using all available data from
all patients (TABLE 3). The factors examined
were weight, several measures
of general (BDI, BAI, RSE) or specific
(EDI-Drive for Thinness, Bulimia, Body
Dissatisfaction and Perfectionism, and
YBC-EDS) psychopathology, and a
measure of quality of life (QlesQ). The
only measure for which a significant
fluoxetine-placebo difference was detected
was the BAI; the mean (SD)
change in BAI per month was −0.70
(0.12) in the fluoxetine group vs −0.22
(0.13) in the placebo group (P=.007;
Bonferroni corrected: P=.07).